首页> 外文期刊>Hepatitis Monthly >Estimation of Diagnosis and Treatment Costs of Non-Alcoholic Fatty Liver Disease: A Two-Year Observation
【24h】

Estimation of Diagnosis and Treatment Costs of Non-Alcoholic Fatty Liver Disease: A Two-Year Observation

机译:非酒精性脂肪肝的诊断和治疗费用估算:两年观察

获取原文
           

摘要

Background: There are insufficient data available on utilization and health care costs of non-alcoholic fatty liver disease. The cost data for different health conditions and services is a major gap in Iranian health system. So this study is the primary or first step towards filling this gap. Objectives: This study aims to estimate the diagnosis and treatment costs of Non-alcoholic Fatty Liver. Patients and Methods: This cross-sectional study was conducted on 528 subjects. The subjects had been diagnosed with non-alcoholic fatty liver. All the subjects had been referred to the Tehran Fatty Liver Clinic, a clinic of the Baqiyatallah Research Center for Gastroenterology and Liver Diseases, in 2009 and they had been observed for 2 years to determine the frequency of health care utilization (physician visit, laboratory tests, medication and cost of sonography). The costs of diagnosis and treatment for each person were estimated in Purchasing Power Parity dollars (PPP$). Results: The average total cost was 5,043 PPP$ per person in the 2 years of observation. Majority of these 528 patients (87.9%) had a BMI ≥ 25 (kg/m2). Also, 33.9% were diagnosed with comorbid diseases such as Diabetes Mellitus (DM), Coronary Artery Disease (CAD), hypertension (HTN) and hypothyroidism (HYPO). Conclusions: The results confirmed that the total costs for non-alcoholic fatty liver among the Iranian adult urban population alone exceeded 1 billion PPP$ per year. These costs can be saved or reduced by effective disease management and early prevention.
机译:背景:关于非酒精性脂肪肝疾病的利用和医疗保健费用,目前没有足够的数据。不同卫生条件和服务的成本数据是伊朗卫生系统的主要缺陷。因此,这项研究是填补这一空白的第一步或第一步。目的:本研究旨在评估非酒精性脂肪肝的诊断和治疗费用。患者和方法:这项横断面研究针对528位受试者进行。受试者已被诊断患有非酒精性脂肪肝。所有受试者均于2009年被转诊至德黑兰脂肪肝诊所,该诊所为巴奇亚拉胃肠病和肝病研究中心的诊所,并进行了为期2年的观察,以确定其医疗保健利用的频率(医师就诊,实验室检查) ,药物和超声检查费用)。每个人的诊断和治疗费用以购买力平价美元(PPP $)估算。结果:在两年的观察中,平均总成本为每人5,043 PPP $。这528名患者中的大多数(87.9%)的BMI≥25(kg / m2)。另外,有33.9%被诊断为合并症,例如糖尿病(DM),冠状动脉疾病(CAD),高血压(HTN)和甲状腺功能减退(HYPO)。结论:结果证实,仅伊朗成人城市人口中,非酒精性脂肪肝的总费用每年就超过10亿美元PPP $。通过有效的疾病管理和早期预防,可以节省或减少这些成本。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号